News
-
VISE symposium explores interoperative fluorescence to light up tumors
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 18, 2017
-
Vanderbilt researchers win an R&D100 Award for MultiWell MicroFormulator
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 13, 2017
-
ChBE research assistant has ‘a good run,’ wins 4 Jeopardy! shows
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 13, 2017
-
Hyperlens crystal capable of viewing living cells in unprecedented detail
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 12, 2017
-
Tech transfer course gives grad students real-world journey
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 9, 2017
-
Campus ASCE chapter invites Hillsboro students to ‘Dream Big’
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 6, 2017
-
ISDE leads $3 million international study of radiation on 3D electronics
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 5, 2017
-
Civil rights pioneer, star Commodore, engineering alumnus Perry Wallace remembered
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 4, 2017
-
Nashville Mayor gives philosophy lesson to Vanderbilt engineering students
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 1, 2017
-
Computer science professors school their peers on the blockchain
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 30, 2017